A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of Seladelpar Administered for 24 Weeks in Adult Patients with Primary Sclerosing Cholangitis (PSC)

Project: Research

StatusActive
Effective start/end date22/11/1931/12/21

Keywords

  • Gastroenterology
  • Primary Sclerosing Cholangitis
  • Clinical trial